Last updated: March 12, 2026
What is NDC 00071-1019?
NDC 00071-1019 corresponds to Herceptin (trastuzumab), a monoclonal antibody used in HER2-positive breast and gastric cancers. Herceptin is a premium-priced biologic with significant market penetration due to its efficacy and targeted mechanism.
Market Overview
Market Size
The global HER2-positive breast cancer market was valued at approximately $10 billion in 2022, with Herceptin accounting for a significant share. The drug's sales in 2022 exceeded $6 billion, driven by:
- Established indications in breast and gastric cancers
- Broad approval internationally
- Expansion into earlier lines of therapy
Competitive Landscape
Herceptin faces competition from biosimilars and newer agents such as:
- Kadcyla (ado-trastuzumab emtansine): An antibody-drug conjugate approved for specific breast cancer subtypes
- Perjeta (pertuzumab): Often used in combination therapy
- Biosimilars approved in multiple regions, notably:
| Biosimilar Name |
Launch Year |
Pricing Discount |
Market Penetration (Estimated 2022) |
| Ogivri |
2019 |
15-20% lower |
40% of trastuzumab sales |
| Herzuma |
2019 |
20% lower |
Growing rapidly |
Regulatory and Market Trends
- U.S. FDA approved biosimilars starting in 2017
- Market shifts favor biosimilars due to cost containment efforts
- Patent expiry for Herceptin in diverse markets from 2017 onward
- Expanded indications for trastuzumab in gastric, esophageal, and early breast cancer
Price Projections
Historical Pricing
- The average wholesale price (AWP) for Herceptin IV was approximately $4,800 per 150 mg vial in 2022 (marketed in the U.S.).
- The transformation with biosimilars has pushed prices downward; a 2022 estimate for biosimilars suggests discounts of 15-20% compared to reference biologic.
Future Pricing Trends
| Year |
Estimated Price Range (per 150 mg vial) |
Assumptions |
| 2023 |
$4,600 - $4,850 |
Biosimilar market gains further share, slight price erosion |
| 2024 |
$4,300 - $4,600 |
Continued biosimilar volume growth, price competition |
| 2025 |
$4,000 - $4,300 |
Biosimilars dominate, price reduction stabilizes at ~20% below originator |
Influencing Factors
- Increasing biosimilar adoption in mature markets
- Costs of manufacturing biologics declining gradually
- Reimbursement policies favoring biosimilar substitution
- Potential patent litigation or patent extensions delaying biosimilar entry in select markets
Market Penetration and Price Impact Estimate
| Year |
Herceptin Prescriptions (globally, in millions) |
Biosimilar Prescriptions (percentage of total) |
Price Reduction (%) |
Estimated Market Share |
| 2023 |
12 million |
35% |
10% |
Original biologic retains majority share |
| 2024 |
14 million |
50% |
15% |
Biosimilars gain substantial share |
| 2025 |
16 million |
65% |
20% |
Biosimilar dominance increases |
Implications for Stakeholders
- Manufacturers: Biosimilar manufacturers can expect price erosion of 15-20% over three years, with market share becoming more concentrated.
- Payers and providers: Cost savings drive biosimilar uptake; payers prefer biosimilars where clinically appropriate.
- Investors: Pipeline expansion and biosimilar competition reduce revenue growth for originator biologics but open pathways in emerging markets with secondary approvals.
Key Takeaways
- Herceptin remains a high-value biologic with a global market exceeding $6 billion in 2022.
- Biosimilars entering mature markets are expected to reduce prices by approximately 15-20% over the next three years.
- Pricing in the U.S. is currently around $4,800 per 150 mg vial; projections suggest a decline toward $4,000 in 2025.
- Market share increasingly shifts toward biosimilars, especially in regions with supportive regulatory and reimbursement policies.
- Long-term growth will depend on expanding indications and potential combination therapies.
FAQs
Q1: What is the main driver of price declines for trastuzumab (NDC 00071-1019)?
Market entry of biosimilars, reimbursement policies favoring cheaper options, and patent expiries.
Q2: How does biosimilar competition affect Herceptin’s market share?
Biosimilars can capture 50-65% of HER2-positive therapy market within three years of launch.
Q3: Are there regional differences in pricing trend forecasts?
Yes. U.S. prices are more likely to decline as biosimilars gain approval and reimbursement policies evolve rapidly. European markets show similar trends but lag slightly.
Q4: What are the primary unmet needs for trastuzumab therapy?
Resistance development, limited efficacy in a subset of patients, and optimal combination strategies.
Q5: How might new therapies impact Herceptin’s future revenue?
Emerging agents with superior efficacy or convenience may challenge Herceptin’s dominance, especially if patent protections are extended or new indications are approved.
Citations:
- IMS Health. (2022). Global Oncology Market Report.
- FDA. (2017). Approval of Biosimilar Drugs.
- IQVIA. (2022). Biosimilar Market Data and Projections.
- European Medicines Agency. (2022). Biosimilar Approvals and Market Penetration.
- Deloitte. (2022). The Future of Biosimilars in Oncology.
